12 May 2020 | News
ZYUS will leverage its bio-pharmaceutical plant technology platform
Image credit- shutterstock.com
ZYUS Life Sciences Inc., a Canada based company dedicated to improving quality of life through research and leadership in bio-pharmaceuticals and the development of innovative cannabinoid-based formulations and product candidates, announced that it is collaborating with the Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) at the University of Saskatchewan, a world leader in developing vaccines and technologies against infectious diseases, to test plant produced antigens in a vaccine for COVID-19.
ZYUS will leverage its bio-pharmaceutical plant technology platform and expertise to develop and express a protein that VIDO-InterVac has identified as a potential antigen for a COVID-19 vaccine. This protein will be isolated by ZYUS in its plant expression system and will provide insights into whether plants can produce antigens that are usable in a COVID-19 vaccine.
“As Canada, and the world, face the challenges of COVID-19, we are proud to partner with VIDO-InterVac to provide Canadian leadership in the development of a vaccine,” said ZYUS CEO, Brent Zettl. “Developing vaccines in plant cells has multiple potential benefits, including the ability to quickly produce a vaccine at scale, having no animal pathogen contaminants, and lower bioreactor processing costs. This is an important initiative for us as an organization, and as citizens looking to make a difference, ZYUS is committing research and development expertise, resources and energy to help find a vaccine now and to develop systems to help respond in the future.”
The approach is one of several that VIDO-InterVac is exploring in an effort to expand vaccine development against this novel coronavirus.